基质金属蛋白酶的含量和活性在脑缺血、颈动脉粥样硬化斑块、脑动静脉畸形、脑动脉瘤等病理状态下明显增高,提示该蛋白酶与脑血管疾病的发生关系密切。动物试验显示,基质金属蛋白酶抑制剂能明显减小脑梗死体积及脑损伤范围,并可稳定易破裂的动脉粥样硬化斑块,抑制脑动脉瘤的膨胀。由此基质金属蛋白酶可能成为防治脑卒中的新靶点。 The content and activity of matrix metalloproteinase in cerebral ischemia, carotid atherosclerotic plaques, cerebral arteriovenous malformations, cerebral aneurysms and other pathological conditions were significantly increased, suggesting that the protease and cerebrovascular disease are closely related. Animal experiments show that matrix metalloproteinase inhibitors can significantly reduce the volume of cerebral infarction and brain damage range, and can stabilize easily ruptured atherosclerotic plaques and inhibit the expansion of cerebral aneurysms. Thus, matrix metalloproteinases may become a new target for prevention and treatment of stroke.